AbiVax’s Partnering Prospects For MicroRNA-based Drug Boosted By Rheumatoid Arthritis Data
Phase IIa RA Results Build On Ulcerative Colitis Promise
Executive Summary
Now that AbiVax's novel anti-inflammatory ABX464 has demonstrated solid safety and efficacy in rheumatoid arthritis and ulcerative colitis, the French biotech is exploring additional programs in chronic inflammatory indications – and looking for a partner.
You may also be interested in...
Finance Watch: Ten IPOs In One Week Bring 2021 Total To 80
Public Company Edition: This year is just six initial public offerings away from matching 2020’s record-breaking total of 86 biopharma IPOs in the US. Also, Idorsia raised $662.5m through the sale of convertible bonds and Cytokinetics closed a $316.3m follow-on offering.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.